New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
13:39 EDTAGN, CS, VRXPershing Square enlists Credit Suisse to help in Allergan effort, WSJ says
William Ackman's Pershing Square has hired Credit Suisse (CS), which is a firm known to have expertise in defending corporate clients against activist investors, for advice on the effort to have Valeant Pharmaceuticals (VRX) take over Allergan (AGN), says the Wall Street Journal. Reference Link
News For AGN;VRX;CS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
11:59 EDTVRXPershing Square reports 5.7% stake in Valeant, will continue talks
Pershing Square expects to conduct discussions with Valeant and other relevant parties regarding strategic acquisitions by or joint ventures with the company, or other similar arrangements. These discussions would be exploratory in nature and there is no assurance that they would lead to a definitive transaction.
March 24, 2015
13:24 EDTVRXContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
March 23, 2015
16:14 EDTAGNPershing Square liquidates stake in Allergan
Subscribe for More Information
09:03 EDTAGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:51 EDTVRXValeant price target raised to $240 from $185 at Susquehanna
Susquehanna raised its price target on Valeant to $240 from $185 to reflect the addition of durable assets and the improved growth trajectory its recent deals brings to its U.S. business. Susquehanna reiterated its Positive rating on Valeant shares.
07:17 EDTVRXAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
17:07 EDTCSCredit Suisse files automatic mixed securities shelf
16:33 EDTVRXStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
March 19, 2015
06:06 EDTCSSunrun powers up for IPO later this year, WSJ reports
Sunrun, a solar-energy company, is said to be working with Credit Suisse (CS) and Goldman Sachs (GS) on a potential IPO for later this year, sources tell The Wall Street Journal, which adds that the company was valued at $1.3B as of March 2014. Other solar companies that have gone public in recent years include residential solar installers like Vivint Solar (VSLR), backed by Blackstone (BX), and SolarCity (SCTY), backed by Tesla's (TSLA) Elon Musk. Reference Link
March 18, 2015
05:45 EDTVRXSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information
March 17, 2015
14:10 EDTVRXIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
13:40 EDTCSAmended settlement agreement announced between Credit Suisse, Freeport
On March 16, an Addendum to the Stipulation and Agreement of Settlement, Compromise and Release was entered into with respect to the consolidated stockholder derivative litigation captioned In Re: Freeport-McMoRan Copper & Gold (FCX) Derivative Litigation, C.A. No. 8145-VCN. The Addendum modifies the terms of the settlement in order to resolve potential derivative claims against Credit Suisse Securities (CS) in connection with its engagement to act as lead financial advisor to the Special Committee of the Board of Directors of Freeport-McMoRan with respect to the company’s 2013 acquisitions of Plains Exploration & Production Company and McMoRan Exploration Co., which potential claims were previously excluded from the settlement as set forth in the Stipulation and Agreement of Settlement, Compromise and Release filed on January 15. As set forth in the Addendum, the original settlement consideration will be increased by $16.25M, consisting of a $10M cash payment to the company by Credit Suisse, and a credit of $6.25M to be redeemable by the company in connection with future assignments Credit Suisse performs. The Supplemental Cash Amount, together with the original settlement amount, less plaintiffs’ attorneys’ fees and expenses as awarded by the Court of Chancery of the State of Delaware, will be distributed to the company’s stockholders as a special dividend. The settlement is subject to specified conditions, including final approval by the Court of Chancery of the State of Delaware. The settling defendants and Credit Suisse vigorously deny all allegations of wrongdoing or fault but entered into the settlement to avoid the costs and distraction of continued litigation.
10:00 EDTCSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
09:01 EDTVRXValeant 7.29M share Spot Secondary priced at $199.00
Deutsche Bank acted as sole book running manager for the offering.
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
06:30 EDTCSCredit Suisse downgraded to Underperform from Neutral at Macquarie
Macquarie downgraded Credit Suisse to Underperform following recent share strength.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use